Skip directly to site content Skip directly to page options Skip directly to A-Z link Skip directly to A-Z link Skip directly to A-Z link
Volume 29, Number 4—April 2023
Research

Effectiveness of BNT162b2 Vaccine against Omicron Variant Infection among Children 5–11 Years of Age, Israel

Aharona Glatman-FreedmanComments to Author , Yael Hershkovitz, Rita Dichtiar, Alina Rosenberg, Lital Keinan-Boker, and Michal Bromberg
Author affiliations: Israel Center for Disease Control, Israel Ministry of Health, Ramat Gan, Israel (A. Glatman-Freedman, Y. Hershkovitz, R. Dichtiar, A. Rosenberg, L. Keinan-Boker, M. Bromberg); Tel Aviv University School of Public Health, Tel Aviv, Israel (A. Glatman-Freedman, M. Bromberg); Haifa University School of Public Health, Haifa, Israel (L. Keinan-Boker)

Main Article

Figure 2

Vaccine effectiveness after second dose of BNT162b2 (Pfizer-BioNTech, https://www.pfizer.com) among children 5–11 years of age, Israel, January 20–February 15, 2022. The center of each symbol is the point estimate; error bars indicate 95% CIs.

Figure 2. Vaccine effectiveness after second dose of BNT162b2 (Pfizer-BioNTech, https://www.pfizer.com) among children 5–11 years of age, Israel, January 20–February 15, 2022. The center of each symbol is the point estimate; error bars indicate 95% CIs.

Main Article

Page created: February 08, 2023
Page updated: March 20, 2023
Page reviewed: March 20, 2023
The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.
file_external